Razpipadon

DB21542InvestigationalSmall molecule

Razpipadon is a small molecule drug. Razpipadon is under investigation in clinical trial NCT04958031 (A Trial of the Safety, Tolerability, and Pharmacodynamics of CVL-871 in Subjects With Dementia-Related Apathy). Razpipadon... Razpipadon has a monoisotopic molecular weight of 389.12 Da.

Mechanism: Pharmacologically active on Dopamine receptor D1
Curator reviewed
Formula / weight: C₁₉H₁₇F₂N₃O₄ · 389.359 g/mol (avg)
Code names: CVL-871 · PF-06669571 · PW-0464, (-)-

Resolves to

Compound

UNII6X6XF88J2MCAS1643489-35-3ChEMBLCHEMBL3697578ChEBI755712PubChem86764103

Structure

InChIKeyZXIPVZWZRQCIRW-UHFFFAOYSA-NSMILESCN1C(=O)NC(=O)C(C)=C1C1=C(C)C=C(OC2=NC=CC=C2OC(F)F)C=C1

Targets

P21728DRD1

What you can answer from here — as of September 23, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

3Clinical trialsPhase, status and sponsor resolved per trial

1+ReferenceStructured and connected to the statements they support

Which drugs share a target with Razpipadon, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account